Amgen (AMGN) fell sharply during Tuesday's intraday trading following the release of phase two trial results for its monthly obesity drug MariTide. Despite the medication demonstrating the ability to reduce an individual's body weight by 20%, the stock tumbled as the results fell short of investor expectations.

Yahoo Finance Health Reporter Anjalee Khemlani delves into the details of the study, exploring the potential strategic routes Amgen could pursue to position the drug competitively in the growing GLP-1 weight loss market.

To watch more expert insights and analysis on the latest market action, check out more Catalysts here.

This post was written by Angel Smith